A share price of Relmada Therapeutics Inc [RLMD] is currently trading at $4.83, up 6.62%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RLMD shares have gain 7.57% over the last week, with a monthly amount glided 9.28%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Relmada Therapeutics Inc [NASDAQ: RLMD] stock has seen the most recent analyst activity on December 22, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $69. Previously, Mizuho upgraded its rating to Outperform on November 19, 2025, and kept the price target unchanged to $10. On December 05, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $1 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $13 on September 17, 2024. Goldman downgraded its rating to a Sell and reduced its price target to $2 on June 05, 2024. Truist downgraded its rating to Hold for this stock on October 14, 2022, and downed its price target to $10. In a note dated October 14, 2022, Guggenheim downgraded a Neutral rating on this stock.
Relmada Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.24 and $5.12. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Relmada Therapeutics Inc [NASDAQ: RLMD] shares were valued at $4.83 at the most recent close of the market. An investor can expect a potential return of 86.34% based on the average RLMD price forecast.
Analyzing the RLMD fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -3.78, Equity is -2.69 and Total Capital is -5.97.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.57 points at the first support level, and at 4.30 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.97, and for the 2nd resistance point, it is at 5.10.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Relmada Therapeutics Inc [NASDAQ:RLMD] is 2.86. Further, the Quick Ratio stands at 2.86, while the Cash Ratio is 0.27.
Transactions by insiders
Recent insider trading involved TRAVERSA SERGIO, Chief Executive Officer, that happened on Dec 15 ’25 when 27500.0 shares were purchased. Chief Financial Officer, Shenouda Maged completed a deal on Dec 15 ’25 to buy 11665.0 shares. Meanwhile, Chief Financial Officer Shenouda Maged bought 0.5 million shares on Nov 05 ’25.
